Nilotinib Vs. Dasatinib in Achieving MR4.5 for Newly Diagnosed Chronic Myeloid Leukemia: Results of the Prospective Randomized Phase 3 Study, JALSG CML212
暂无分享，去创建一个
T. Naoe | T. Miyamoto | N. Takahashi | I. Matsumura | N. Iriyama | C. Nakaseko | Y. Miyazaki | H. Kiyoi | T. Tauchi | M. Okada | Y. Atsuta | N. Asou | K. Kakihana | K. Fujimaki | S. Fujisawa | S. Ohtake | K. Ohnishi | Mio Kurata | E. Sakaida | Y. Minami | T. Ono | Y. Ogasawara | Y. Kobayashi